OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
194A$1600.0057

WOLVES HAND Co Ltd

Healthcare Facilities & ServicesVerified

WOLVES HAND Co Ltd has a market capitalization of ¥12.05 billion and a price-to-earnings ratio of 20.32, indicating a moderate valuation relative to earnings. The company's price-to-book ratio of 4.44 suggests that the market values the company at a premium to its book value, which may reflect intangible assets or growth expectations. The liquidity position is characterized by ¥895.33 million in cash and equivalents, but the current ratio of 0.71 indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity constraints. In terms of profitability, the company's return on equity of 21.84% and return on assets of 9.8% are strong, suggesting efficient use of equity and assets to generate profits. The operating margin, calculated as operating income of ¥900.01 million on revenue of ¥5.46 billion, is 16.5%, which is a key performance indicator for the healthcare services industry. The company's gross margin of 27.1% is also robust, indicating effective cost control in its core operations. The company's business is diversified across veterinary hospital operations, pet salons, software provision, education seminars, and medical equipment manufacturing. The veterinary hospital and pet salon operations are likely the primary revenue drivers, but the company's exposure to geographic concentration is not disclosed in the provided data. The company's revenue is derived from a mix of services and products, but the exact contribution of each segment is not specified. Looking at the growth trajectory, the company's capital expenditure of -¥116.03 million suggests a reduction in investment in physical assets, which could indicate a focus on cost optimization or a shift in strategic priorities. The company's free cash flow of ¥827.20 million is positive, indicating that it generates sufficient cash to fund operations and potentially reinvest in the business. However, the outlook for the next fiscal year is not provided, so the direction of revenue growth remains uncertain. The risk assessment highlights a medium liquidity risk, with the company's net cash position being negative after accounting for total debt of ¥2.54 billion. The dilution risk is assessed as low, and there are no adjustments applied to the valuation metrics, suggesting that the company's capital structure is stable. The debt-to-equity ratio of 0.93 indicates a balanced capital structure, with debt financing playing a significant but not overwhelming role in the company's capital base. Recent events and filings are not detailed in the provided data, so the impact of any recent developments on the company's operations and financial position is not quantifiable. The company's strategic direction and operational performance will be critical in determining its future growth and profitability.

30-day price · 194A-380.00 (-21.4%)
Low$1316.00High$2006.00Close$1396.00As of21 May, 00:00 UTC
Profile
CompanyWOLVES HAND Co Ltd
Ticker194A.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. WOLVES HAND Co Ltd operates veterinary hospitals and pet salons, provides veterinary hospital software, distributes veterinary medical education seminars, and manufactures and sells medical equipment and instruments.

Classification. WOLVES HAND is classified in the Healthcare sector under Healthcare Services & Equipment, with a confidence level of 0.92.

WOLVES HAND Co Ltd has a market capitalization of ¥12.05 billion and a price-to-earnings ratio of 20.32, indicating a moderate valuation relative to earnings. The company's price-to-book ratio of 4.44 suggests that the market values the company at a premium to its book value, which may reflect intangible assets or growth expectations. The liquidity position is characterized by ¥895.33 million in cash and equivalents, but the current ratio of 0.71 indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity constraints. In terms of profitability, the company's return on equity of 21.84% and return on assets of 9.8% are strong, suggesting efficient use of equity and assets to generate profits. The operating margin, calculated as operating income of ¥900.01 million on revenue of ¥5.46 billion, is 16.5%, which is a key performance indicator for the healthcare services industry. The company's gross margin of 27.1% is also robust, indicating effective cost control in its core operations. The company's business is diversified across veterinary hospital operations, pet salons, software provision, education seminars, and medical equipment manufacturing. The veterinary hospital and pet salon operations are likely the primary revenue drivers, but the company's exposure to geographic concentration is not disclosed in the provided data. The company's revenue is derived from a mix of services and products, but the exact contribution of each segment is not specified. Looking at the growth trajectory, the company's capital expenditure of -¥116.03 million suggests a reduction in investment in physical assets, which could indicate a focus on cost optimization or a shift in strategic priorities. The company's free cash flow of ¥827.20 million is positive, indicating that it generates sufficient cash to fund operations and potentially reinvest in the business. However, the outlook for the next fiscal year is not provided, so the direction of revenue growth remains uncertain. The risk assessment highlights a medium liquidity risk, with the company's net cash position being negative after accounting for total debt of ¥2.54 billion. The dilution risk is assessed as low, and there are no adjustments applied to the valuation metrics, suggesting that the company's capital structure is stable. The debt-to-equity ratio of 0.93 indicates a balanced capital structure, with debt financing playing a significant but not overwhelming role in the company's capital base. Recent events and filings are not detailed in the provided data, so the impact of any recent developments on the company's operations and financial position is not quantifiable. The company's strategic direction and operational performance will be critical in determining its future growth and profitability.
Key takeaways
  • WOLVES HAND Co Ltd has a strong return on equity of 21.84%, indicating efficient use of equity to generate profits.
  • The company's liquidity position is constrained, with a current ratio of 0.71, suggesting potential short-term financial pressures.
  • The veterinary hospital and pet salon operations are likely the primary revenue drivers, but the exact contribution of each segment is not specified.
  • The company's free cash flow of ¥827.20 million is positive, indicating sufficient cash to fund operations and potential reinvestment.
  • The debt-to-equity ratio of 0.93 suggests a balanced capital structure, with debt financing playing a significant but not overwhelming role.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$5.46B
Gross profit$1.48B
Operating income$900.0M
Net income$593.0M
R&D
SG&A
D&A
SBC
Operating cash flow$948.6M
CapEx-$116.0M
Free cash flow$827.2M
Total assets$6.05B
Total liabilities$3.33B
Total equity$2.72B
Cash & equivalents$895.3M
Long-term debt$2.54B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$1600.00
Market cap$12.05B
Enterprise value$13.69B
P/E20.3
Reported non-GAAP P/E
EV/Revenue2.5
EV/Op income15.2
EV/OCF14.4
P/B4.4
P/Tangible book4.4
Tangible book$2.72B
Net cash-$1.64B
Current ratio0.7
Debt/Equity0.9
ROA9.8%
ROE21.8%
Cash conversion1.6%
CapEx/Revenue-2.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric194AActivity
Op margin16.5%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin10.9%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin27.1%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-2.1%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity93.0%71.3% medp25 19.0% · p75 91.7%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 09:43 UTC#697a9f56
Market quoteclose JPY 1600.00 · shares 0.01B diluted
no public URL
2026-05-10 09:43 UTC#66236a71
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 09:45 UTCJob: 5063cd41